248 related articles for article (PubMed ID: 24422672)
21. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).
Slingluff CL; Petroni GR; Molhoek KR; Brautigan DL; Chianese-Bullock KA; Shada AL; Smolkin ME; Olson WC; Gaucher A; Chase CM; Grosh WW; Weiss GR; Wagenseller AG; Olszanski AJ; Martin L; Shea SM; Erdag G; Ram P; Gershenwald JE; Weber MJ
Clin Cancer Res; 2013 Jul; 19(13):3611-20. PubMed ID: 23620404
[TBL] [Abstract][Full Text] [Related]
22. RAF1-rearranged spindle cell tumour: report of two additional cases with identification of a novel FMR1-RAF1 fusion.
Zhang T; Wang Q; Yi X; Zhu P
Virchows Arch; 2021 Dec; 479(6):1245-1253. PubMed ID: 34459981
[TBL] [Abstract][Full Text] [Related]
23. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
24. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
25. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
27. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
28. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
[TBL] [Abstract][Full Text] [Related]
29. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Botton T; Yeh I; Nelson T; Vemula SS; Sparatta A; Garrido MC; Allegra M; Rocchi S; Bahadoran P; McCalmont TH; LeBoit PE; Burton EA; Bollag G; Ballotti R; Bastian BC
Pigment Cell Melanoma Res; 2013 Nov; 26(6):845-51. PubMed ID: 23890088
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
[TBL] [Abstract][Full Text] [Related]
31. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
Paglino C; Procopio G; Sabbatini R; Bellmunt J; Schmidinger M; Bearz A; Bamias A; Melichar B; Imarisio I; Tinelli C; Porta C
Anticancer Res; 2013 Nov; 33(11):4999-5004. PubMed ID: 24222142
[TBL] [Abstract][Full Text] [Related]
32. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
33. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.
Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab.
Wagenseller AG; Shada A; D'Auria KM; Murphy C; Sun D; Molhoek KR; Papin JA; Dutta A; Slingluff CL
J Transl Med; 2013 Sep; 11():218. PubMed ID: 24047116
[TBL] [Abstract][Full Text] [Related]
35. BRAF-rearranged spindle cell mesenchymal neoplasm with a predominant lipofibromatosis-like neural tumor pattern and co-expression of CD34, S100 protein, and markers associated with perineurial differentiation: A rare case with potential diagnostic pitfall.
Sun K; Ru GQ; Zhao M
J Cutan Pathol; 2022 Mar; 49(3):278-283. PubMed ID: 34632612
[TBL] [Abstract][Full Text] [Related]
36. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
[TBL] [Abstract][Full Text] [Related]
37. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
38. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Waidmann O; Hofmann WP; Zeuzem S; Trojan J
J Hepatol; 2011 Feb; 54(2):396-8. PubMed ID: 21111506
[No Abstract] [Full Text] [Related]
39. Spindle cell sarcoma with
Fujikawa T; Uemura S; Yoshida M; Hyodo S; Kozaki A; Saito A; Kishimoto K; Ishida T; Mori T; Uematsu A; Morita K; Hatakeyama T; Tamura A; Yamamoto N; Komatsu M; Soejima T; Hasegawa D; Kosaka Y
Oncol Lett; 2022 Dec; 24(6):452. PubMed ID: 36380878
[TBL] [Abstract][Full Text] [Related]
40. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
